|
CME
Educational programs require versions of browsers developed within the last 2 years.
Certain program content and other materials are issued as PDF files and require Adobe Acrobat Reader to access and print. Click here to download the latest version of the software.
Click here to read our privacy policy for supplements and educational programs.
CME A Bridge to the Future: Redefining the Scientific Paradigm in the Treatment of Schizophrenia
September 2011 CE/CME expired
 Current treatment of schizophrenia is limited in its scope, improving only positive symptoms and failing to improve negative and cognitive deficits, the real causes of functional disability. But there is some good news on the schizophrenia front—a potential breakthrough in understanding the pathophysiology of both hyper- and hypodopaminergia in the mesolimbic and mesocortical pathways in schizophrenia. The past 2 decades have seen a surge in research findings implicating glutamate dysfunction as possibly the root of neurochemical pathology in schizophrenia, and the new model promises to take efforts to understand schizophrenia in a new direction. This supplement looks into the future of schizophrenia treatment and the remarkable paradigm shift from dopamine to glutamate as a central focus for this most challenging brain disorder.
This content is based on a live continuing medical education (CME) satellite symposium, A Bridge to the Future: Redefining the Scientific Paradigm in the Treatment of Schizophrenia, held April 16, 2011, in Chicago, Illinois, as part of the annual meeting of the American Academy of Clinical Psychiatrists (AACP). This supplement was submitted by Medical Education Resources and Consensus Medical Communications and supported by an educational grant from Genentech. It was peer reviewed by Current Psychiatry.
Full text
PDF
CME Identifying and Managing Patients With Mixed States in Bipolar Disorder
May 2011 CE/CME expired
Many patients with bipolar disorder experience manic and depressive symptoms simultaneously. These mixed states may complicate diagnosis as well as treatment.
This activity will help clinicians identify mixed symptoms in patients with bipolar disorder and implement effective treatment strategies designed to address these complex clinical situations.
This e-newsletter was submitted by SciMed, LLC and supported by an educational grant from Bristol-Myers Squibb and Otsuka America Pharmaceuticals Inc. It was peer reviewed by Current Psychiatry.
Full text
CME Metabolic Comorbidities in Patients With Bipolar Disorder
April 2011 CE/CME expired
Medical comorbidities, particularly cardiometabolic diseases, are highly prevalent among patients with bipolar disorder. A bidirectional relationship exists between psychiatric disorders and medical conditions, which can negatively impact the course of disease and has important implications for management.
This activity will help clinicians recognize the clinical overlap and interactions between metabolic comorbidities and psychiatric illness, and develop effective treatment strategies that reduce the burden of medical conditions in patients with bipolar disorder.
This e-newsletter was submitted by SciMed, LLC and supported by an educational grant from Bristol-Myers Squibb and Otsuka America Pharmaceuticals Inc. It was peer reviewed by Current Psychiatry.
Full text
CME Bipolar Disorder: Differential Diagnosis and Evidence-Based Treatment Strategies
November 2010 CE/CME expired
 Bipolar disorder (BD) ranks high among the most prevalent and frequently underdiagnosed and undertreated affective disorders in the United States. Despite the growth in research in recent years, an estimated 69% of people with BD have been misdiagnosed; most notably, patients with BD receive a mean of 3.5 other diagnoses and consult 4 physicians before being accurately diagnosed. BD increases the risk for suicide and is associated with several psychiatric and medical comorbidities, including substance misuse, anxiety disorders, cardiovascular disease, metabolic syndrome, and hyperten¬sion. An increasing body of evidence suggests that when appropriate pharmacotherapeutic interventions are initiated early in the course of the disorder, the ultimate prognosis is substantially improved. Longitudinal data on the management of patients with BD, including monitoring for efficacy, safety, adherence, and comorbidities, are available to provide practical, clinically applicable information.
This multimedia resource compendium is designed to educate healthcare professionals about recent developments in the differential diagnosis and medical management of BD, with a focus on a patient-centered, individualized approach to treatment. Psychiatrists and neurologists, as well as pharma¬cists, primary care physicians, and other multidisciplinary team members, may find this compendium of particular value as a clinical reference tool to help improve care and outcomes of their patients with BD.
This supplement was submitted by Albert Einstein College of Medicine, Montefiore Medical Center, the College of Psychiatric and Neurologic Pharmacists (CPNP), and Asante Communications, LLC, and supported by educational grants from Eli Lilly and Company and Janssen, Division of Ortho-McNeil Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs.
Full text
Download the PDF
CME Long-Term Treatment of Schizophrenia: Minimizing Side Effect Burden to Improve Patient Outcomes
November 2010 CE/CME expired
Management of schizophrenia by psychiatrists commonly is limited to interventions mitigating the positive and, to a lesser extent, negative symptoms that are the most immediate and often considered the most debilitating. However, side effects associated with antipsychotics used to treat these symptoms can have a negative impact on overall patient outcome.
This activity will help clinicians understand the importance of evaluating different antipsychotic side effect profiles when treating patients with schizophrenia, assess the impact of side effects on a patient’s recovery from schizophrenia, and predict potential side effect risks associated with different antipsychotic medications based on their neuroreceptor binding properties.
This e-newsletter was submitted by SciMed and supported by an educational grant from Merck. It was peer reviewed by Current Psychiatry. This CME activity is part of a curriculum that discusses effective management of patients with schizophrenia and includes virtual patient visits with Jason. These interactive activities highlight the importance of patient-directed goals in managing patients attempting to achieve functional recovery from schizophrenia. For more information and to view the Virtual Patient Visits, visit the Virtual Clinic.
Full text
CME Effective Strategies for Patients With Complex Depression in Psychiatric Practice
November 2010 CE/CME expired
 MDD is a serious chronic illness that affects the lives of millions of patients and their families, and poses challenges for psychiatrists caring for these individuals. Despite the availability of effective treatments, many patients with MDD fail to achieve remission, the primary goal of therapy. More than half of patients either do not respond or only partially respond to first-line antidepressants. In addition, comorbid chronic medical conditions complicate the clinical presentation and treatment decisions, and require special consideration. A number of effective pharmacologic treatment strategies have been studied for patients in these challenging situations, including switching to another approved antidepressant, combining treatment with an approved antidepressant agent, and augmenting with an agent of a different class.
This supplement was submitted by SciMed and supported by an educational grant from AstraZeneca. It was peer reviewed by Current Psychiatry and Annals of Clinical Psychiatry.
Full text
Download the PDF
Virtual Clinic Powered by  with content provided by its educational partners
Featured Case
Lisa Visit 3: A woman with bipolar disorder who may be experiencing side effects due to her current pharmacological treatment
"I've been feeling restless and I'm having trouble sleeping."
Meet and Treat Lisa in the Virtual Clinic, designed to replicate the real-world experiences of busy clinicians in a private practice setting. These activities will focus on the challenges in ongoing maintenance therapy of patients with bipolar disorder and will present evidence-based intervention strategies to both focus on patient-identified concerns and overcoming obstacles to long-term wellness.
For more cases, click here
CME Expanding the Treatment Paradigm in Patients With Schizophrenia: Beyond Psychotic Symptoms
October 2010 CE/CME expired
Management of schizophrenia by psychiatrists is commonly limited to interventions mitigating the positive symptoms that are the most immediate and often considered the most debilitating. A broader understanding of the impact of negative symptoms and cognitive impairment is needed to improve patients’ overall health and ability to function.
This activity will help clinicians understand the importance of cognitive and negative symptoms in functional impairment, describe mechanisms of action for various pharmacologic medications and how they impact efficacy, and address the importance of improving patient outcomes by developing treatment strategies designed to address nonpsychotic symptom domains of schizophrenia.
This e-newsletter was submitted by SciMed and supported by an educational grant from Merck. It was peer reviewed by Current Psychiatry.
This CME activity is part of a curriculum that discusses effective management of patients with schizophrenia and includes virtual patient visits with Jason. These interactive activities highlight the importance of patient-directed goals in managing patients attempting to achieve functional recovery from schizophrenia. For more information and to view the Virtual Patient Visits, visit the Virtual Clinic.
Full text
CME Differential Diagnosis and Therapeutic Management of Schizoaffective Disorder
October 2010 CE/CME expired
 Patients with schizoaffective disorder (SAD) meet criteria for schizophrenia, while also meeting criteria for major depressive disorder or mania, and will have periods of psychosis without mood disorder symptoms. SAD remains underdiagnosed, in part because it is frequently confused with other psychiatric disorders with overlapping diagnostic criteria—chiefly schizophrenia, bipolar disorder, and major depressive disorder. Understanding collaborative management of patients with SAD is an important educational imperative for psychiatrists and other health care professionals. Considerable gaps in level-1 evidence mirror the need for psychiatrists to exchange insights into this heterogeneous clinical construct and its clinical management.
This activity is jointly sponsored by Albert Einstein College of Medicine, Montefiore Medical Center, and Asante Communications, LLC, and is supported by an educational grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, administered by Ortho-McNeil-Janssen Scientific Affairs, LLC.
CME Proceedings and Data From the Bipolar Summit
March 2010 CE/CME expired
 Bipolar disorder (BD) is a chronic psychological illness of substantial morbidity and mortality characterized by frequent episodes of mania and depression. This disorder is of particular importance to health care professionals given that it affects up to 3% of the general population and causes a significant impact on the patient's quality of life, as well as a considerable economic burden on both the individual and society.
In November 2009, an expert panel of 7 nationally recognized psychiatric experts convened at the Bipolar Summit. Summit members presented clinical data about six statements that broadly addressed recent advances in the understanding of Bipolar Disorder. The experts voted on the validity of each statement in light of the strength of the available evidence; the results of the experts’ ratings were then compared with clinical psychiatrists in the community using a national survey, and recommendations were made for future research. This activity will provide an evidence-based evaluation surrounding the treatment of patients with BD using pharmacologic and psychosocial therapies. The six areas of clinical focus that are explored in this supplement include brain alterations in bipolar patients, bipolar NOS (not otherwise specified) diagnosis and treatment, residual bipolar-related symptoms, use of antidepressants in the treatment of bipolar disorder, treating substance-abuse disorders in bipolar patients, and use of second-generation antipsychotics as mood stabilizers. This activity is hosted by the University of Minnesota and Consensus Medical Communications. This activity was funded through an educational grant from Janssen, L.P. This grant is administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
Full text
Download the PDF
CME Maintaining wellness in patients with bipolar disorder: moving beyond efficacy to effectiveness
October 2009 CE/CME expired
 Bipolar disorder (BD) is challenging to diagnose because it is often comorbid with other psychiatric illnesses, drug and alcohol abuse, and physical illness. Since BD is a chronic disorder, long-term treatment with both pharmacologic and psychosocial therapies is needed.
This activity will help clinicians develop an evidence-based approach to therapy, integrate nonpharmacologic management strategies into treatment programs, and create long-term treatment strategies designed to optimize patient outcomes while minimizing medication-related adverse events.
This supplement was submitted by SciMed and supported by an educational grant from AstraZeneca. It was peer reviewed by Current Psychiatry and Annals of Clinical Psychiatry.
Full text
Download the PDF
CME Diagnosing and managing psychotic and mood disorders
December 2008 CE/CME expired
 The diagnosis and management of psychotic and mood disorders is an evolving process and an important topic for continuing medical education. To facilitate a dialogue on the identification and treatment of psychotic and mood disorders, we have invited 4 expert faculty members to present actual patient cases. The learning objectives of this CME program are: (1) to achieve early and accurate diagnosis of patients with psychotic and mood disorders, using effective screening tools as needed; (2) to determine the most appropriate monotherapy or combination therapy for short- and long-term treatment; and (3) to review the mechanisms of action and metabolism of medications used for these conditions.This CME activity was developed through the sponsorship of the University of Cincinnati and supported by an educational grant from AstraZeneca.
Full text
Download the PDF
Complete program material, including podcasts and newsletters
CME Stay awake! Understanding, diagnosing, and successfully managing narcolepsy
December 2007 CE/CME expired
 Narcolepsy is a chronic, neurologic sleep disorder resulting from the dysregulation of sleep-wake cycles. Although the exact etiology of narcolepsy is still unknown, clinical understanding of the underlying causes as well as the treatment options have increased in the last decade. This supplement will review the epidemiology, diagnosis, pathophysiology, pharmacology, and treatment strategies for narcolepsy, and is intended to provide a current, evidence-based examination of narcolepsy. This CME activity is sponsored by The Chatham Institute and supported by an educational grant from Jazz Pharmaceuticals.
Download the PDF
|
